Home Institutions Dana-Farber Cancer Institute clinical trials Institution Directory
Clinical trials at Dana-Farber Cancer Institute Sites in Boston, MA
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:37 PM EST
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1323
Current sort
Recently updated
Campus scope
Dana-Farber Cancer Institute, Boston, MA
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 745–756 of 1,323 matching trials with a site at Dana-Farber Cancer Institute, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Renal Cell Carcinoma, Unresectable Advanced Renal Cell Carcinoma, Metastatic Ncc Renal Cell Carcinoma
Interventions Cabozantinib, Nivolumab, Ipilimumab Drug
Lead sponsor Bradley A. McGregor, MD Other
Eligibility 18 Years and older
Enrollment 60 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2020 – 2027
U.S. locations 4
States / cities Boston, Massachusetts • Dallas, Texas
Conditions Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer, Non-adenocarcinoma Prostate Cancer, Refractory Germ-cell, High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
Interventions Ipilimumab, Nivolumab Drug
Lead sponsor Dana-Farber Cancer Institute Other
Eligibility 18 Years and older
Enrollment 100 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2017 – 2027
U.S. locations 6
States / cities La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Conditions Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Interventions INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab, ADG126 Drug
Lead sponsor Incyte Corporation Industry
Eligibility 18 Years and older
Enrollment 570 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2029
U.S. locations 11
States / cities Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 7 more
Conditions Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS)
Interventions Lenalidomide Drug
Lead sponsor Dana-Farber Cancer Institute Other
Eligibility 18 Years and older
Enrollment 12 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2015 – 2026
U.S. locations 1
States / cities Boston, Massachusetts
Conditions HER2-positive Breast Cancer
Interventions tucatinib, placebo, T-DM1 Drug
Lead sponsor Seagen, a wholly owned subsidiary of Pfizer Industry
Eligibility 18 Years and older
Enrollment 466 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2019 – 2029
U.S. locations 321
States / cities Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more
Conditions Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
Interventions disitamab vedotin Drug
Lead sponsor Seagen, a wholly owned subsidiary of Pfizer Industry
Eligibility 18 Years and older
Enrollment 120 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2028
U.S. locations 75
States / cities Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more
Conditions Relapsed/Refractory Small Cell Lung Cancer
Interventions Tarlatamab Drug
Lead sponsor Amgen Industry
Eligibility 18 Years and older
Enrollment 222 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2021 – 2027
U.S. locations 16
States / cities Birmingham, Alabama • Little Rock, Arkansas • Newark, Delaware + 13 more
Conditions Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Interventions silevertinib (BDTX-1535) monotherapy Drug
Lead sponsor Black Diamond Therapeutics, Inc. Industry
Eligibility 18 Years and older
Enrollment 200 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2027
U.S. locations 25
States / cities Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more
Conditions Solid Tumors
Interventions INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890 Drug
Lead sponsor Incyte Corporation Industry
Eligibility 18 Years and older
Enrollment 710 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2027
U.S. locations 13
States / cities Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more
Conditions Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions tisotumab vedotin, pembrolizumab, carboplatin, cisplatin Drug
Lead sponsor Seagen, a wholly owned subsidiary of Pfizer Industry
Eligibility 18 Years and older
Enrollment 350 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2018 – 2027
U.S. locations 124
States / cities Encinitas, California • La Jolla, California • Sacramento, California + 57 more
Conditions Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Interventions Apalutamide, Androgen Deprivation Therapy Drug
Lead sponsor M.D. Anderson Cancer Center Other
Eligibility 18 Years and older · Male only
Enrollment 120 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2029
U.S. locations 6
States / cities Gilbert, Arizona • Chicago, Illinois • Kansas City, Kansas + 3 more
Conditions NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
Interventions Pembrolizumab, PEMETREXED, CARBOPLATIN, PACLITAXEL, InVision Drug · Diagnostic Test
Lead sponsor Julia K. Rotow, MD Other
Eligibility 18 Years and older
Enrollment 40 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2020 – 2026
U.S. locations 5
States / cities Boston, Massachusetts • Brighton, Massachusetts • South Weymouth, Massachusetts About this Dana-Farber Cancer Institute institution page
What this page lists ClinicalTrials.gov records that list Dana-Farber Cancer Institute in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , trials led by Dana-Farber Cancer Institute at any site , browse by condition , or browse by U.S. city .